Common blood pressure medicine blocks molecule that can trigger the disease
A drug commonly used to control high blood pressure may also help prevent the onset of Type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida (UF) in Gainesville.
The study was published online this week in the Journal of Clinical Investigation.
“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, MD, a researcher at the Barbara Davis Center for Childhood Diabetes and associate professor of medicine at CU Anschutz. “We made this discovery using a supercomputer, on the lab bench, in mice and in humans.”
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children. It is on the World Health Organization’s list of essential drugs.
But like many drugs used for one condition, Michels and his colleagues found it useful for something totally unrelated.
Some 60 percent of people at risk of getting Type 1 diabetes possess the DQ8 molecule which significantly increases the chance of getting the disease. The researchers believed that if they could block specifically the DQ8 molecule they could also block the onset of the disease.
“All drugs have off-target effects. If you take too much acetaminophen you can hurt your liver,” Michels said. “We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove.”
After running thousands of drugs through the supercomputer, they found that methyldopa not only blocked DQ8, but it didn’t harm the immune function of other cells like many immunosuppressant drugs do.
The research spanned 10 years and its efficacy was shown in mice and in 20 Type 1 diabetes patients who took part in a clinical trial at the Barbara Davis Center at the University of Colorado School of Medicine.
“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes,” Michels said. “The goal with this drug is to delay or prevent the onset of the disease among those at risk.”
The drug is taken orally, three times a day.
Implications for treatment
Michels and UF Health researcher David Ostrov, PhD, hope this same approach of blocking specific molecules can be used in other diseases.
“This study has significant implications for treatment of diabetes and also other autoimmune diseases,” said Ostrov, associate professor of pathology, immunology and laboratory medicine in the UF College of Medicine and a member of the UF Health Cancer Center, Genetics Institute and Center for NeuroGenetics. “This study suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”
The next step will be a larger clinical trial sponsored by the National Institutes of Health in spring.
“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at risk for the disease,” Michels said. “This is very significant development.”
The Latest on: Type 1 diabetes
Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
on May 23, 2018 at 10:43 am
A healthy market for certain Type-2 diabetes treatments has been good to Eli Lilly and Co. (LLY) . Senior vice president Enrique Conterno said Tuesday, May 22, that the company's Trulicity drug is benefiting from the growth of glucagon-like peptide-1 (GLP ... […]
Why Does Diabetes Plague This Canadian Province?
on May 23, 2018 at 8:00 am
The health organization compiled information from Statistics Canada, the Public Health Agency of Canada and the National Diabetes Surveillance System, and the data shows a stark reality: The prevalence of diagnosed Type 1 and Type 2 diabetes in ... […]
Text messages provide support for people with diabetes
on May 23, 2018 at 7:30 am
The group was 52 per cent male and 48 per cent female. Sixty-five per cent had type 2 diabetes and 35 per cent had type 1. Ethnically, 23 per cent identified as Māori, 13 per cent as Pacific, 5 per cent as Asian and 49 per cent as New Zealand European. […]
$1 for 12 acres north of the Dayton Mall? Miami Twp. OKs purchase plan.
on May 23, 2018 at 5:39 am
Contributions will typically be tax-deductible. SAN ANTONIO, Texas — Years of testing remain, but UT Health San Antonio researchers say they’ve cured Type 1 diabetes in mice. In peer-reviewed paper, they say a “gene transfer” can “wake up ... […]
Does Marriage Increase Risk of Diabetes?
on May 23, 2018 at 4:55 am
And it is estimated 1,5 million deaths are caused by the disease ... In the current study, researchers examined whether the heightened risk of developing type 2 diabetes of an obese woman, for example, was merely a result of her own body weight, or ... […]
Logan Merwin: A Boy with Diabetes and a Hot Wheels Dream
on May 23, 2018 at 2:37 am
He's also been living with type 1 since just 17 months old, so it's all he's ever known. Through his family's advocacy efforts, this 11-year-old has a unique chance to channel his passion for cars into raising the profile of diabetes across the country. […]
Some startups say they can reverse diabetes. Not all scientists agree
on May 22, 2018 at 5:50 pm
First, some background for those who are fortunate enough to not be affected by diabetes: Type 1 diabetes occurs when the pancreas produces little to no insulin. Type 2 diabetes is when one’s body either resists or does not produce enough insulin. […]
Are apples good for diabetes?
on May 22, 2018 at 6:47 am
Find out about the causes, symptoms diagnosis and treatments. What is the difference between diabetes 1 and diabetes 2? Learn all about type 1 and type 2 diabetes and the differences between the two conditions in our article about the diabetes mellitus ... […]
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
on May 22, 2018 at 5:07 am
BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition ... […]
Semaglutide found to be effective against type 2 diabetes
on May 21, 2018 at 2:44 pm
(HealthDay)—Semaglutide is safe and effective for the treatment of type 2 diabetes, according to a review published ... The researchers found that subcutaneous semaglutide (0.5 and 1 mg) reduced HbA1c by 1.01 percent (95 percent confidence interval ... […]
via Google News and Bing News